A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV

Sahabi Kabir Sulaiman (), Muhammad Sale Musa, Fatimah Isma’il Tsiga-Ahmed, Abdulwahab Kabir Sulaiman and Abdulaziz Tijjani Bako
Additional contact information
Sahabi Kabir Sulaiman: Yobe State University Teaching Hospital
Muhammad Sale Musa: Yobe State University Teaching Hospital
Fatimah Isma’il Tsiga-Ahmed: Bayero University Kano/Aminu Kano Teaching Hospital
Abdulwahab Kabir Sulaiman: Murtala Muhammad Specialist Hospital
Abdulaziz Tijjani Bako: Houston Methodist

Nature Human Behaviour, 2024, vol. 8, issue 1, 100-114

Abstract: Abstract People living with HIV (PLHIV) are at higher risk of poor outcomes of SARS-CoV-2 infection. Here we report the pooled prevalence of COVID-19 vaccine acceptance/uptake and determinants among this vulnerable population of PLHIV based on a systematic review and meta-analysis of studies published by 25 August 2023. Among the 54 included studies (N = 167,485 participants), 53 (N = 166,455) provided data on vaccine acceptance rate, while 27 (N = 150,926) provided uptake data. The global prevalences of COVID-19 vaccine acceptance and uptake were 67.0% and 56.6%, respectively. Acceptance and uptake rates were 86.6% and 90.1% for the European Region, 74.9% and 71.6% for the Region of the Americas, 62.3% and 78.9% for the South-East Asian Region, 64.6% and 19.3% for the Eastern Mediterranean Region, 58.0% and 35.5% for the African Region, and 57.4% and 44.0% for the Western Pacific Region. The acceptance rate increased from 65.9% in 2020 to 71.0% in 2022, and the uptake rate increased from 55.9% in 2021 to 58.1% in 2022. Men, PLHIV aged ≥40 years and those who had recently received the influenza vaccine were more likely to accept and receive the COVID-19 vaccine. Factors associated with lower uptake included Black race, other races (Latinx/Hispanic/mixed race), low education level and being unemployed. Vaccine-related factors associated with higher acceptance included belief in vaccine effectiveness, vaccine trust, perceived high susceptibility to SARS-CoV-2 infection and fear of potential COVID-19 effect in PLHIV. Sustained efforts and targeted interventions are needed to reduce regional disparities in COVID-19 vaccine uptake among PLHIV.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41562-023-01733-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nathum:v:8:y:2024:i:1:d:10.1038_s41562-023-01733-3

Ordering information: This journal article can be ordered from
https://www.nature.com/nathumbehav/

DOI: 10.1038/s41562-023-01733-3

Access Statistics for this article

Nature Human Behaviour is currently edited by Stavroula Kousta

More articles in Nature Human Behaviour from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().